The Prevalence and Forecast Prevalence of Overactive Bladder in the Medicare Population

G. Puckrein, D. Walker, Liou Xu, Peter Congdon, K. Gooch
{"title":"The Prevalence and Forecast Prevalence of Overactive Bladder in the Medicare Population","authors":"G. Puckrein, D. Walker, Liou Xu, Peter Congdon, K. Gooch","doi":"10.1177/1179561119847464","DOIUrl":null,"url":null,"abstract":"Objectives: To determine current and future prevalence of overactive bladder (OAB) among Medicare fee-for-service beneficiaries in the United States. Methods: Prevalence of OAB in US adults ⩾ 65 years was determined using the 2013 Medicare Beneficiary Part B Carrier Claims File, Part D Drug Event File, and Medicare Beneficiary Annual Summary File. Prevalence for 2027 was forecasted with US Census population projections. Regional projections were based on applying national OAB rates by age, sex, and race/ethnicity to zip code tabulation area beneficiary populations. Results: In the 2013 dataset, the prevalence of OAB was 7.2% (male: 7.7%; female: 6.7%). Across demographic categories, prevalence was the highest among those aged more than 74 years (9.3%), identifying as White (7.4%), and residing in urban areas (7.5%). By 2027, OAB is projected to increase by 48.1%. Discussion: OAB affects a substantial proportion of the US fee-for-service beneficiary population, with the prevalent population projected to rise substantially by 2027.","PeriodicalId":89908,"journal":{"name":"Clinical medicine insights. Urology","volume":"5 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical medicine insights. Urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/1179561119847464","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

Objectives: To determine current and future prevalence of overactive bladder (OAB) among Medicare fee-for-service beneficiaries in the United States. Methods: Prevalence of OAB in US adults ⩾ 65 years was determined using the 2013 Medicare Beneficiary Part B Carrier Claims File, Part D Drug Event File, and Medicare Beneficiary Annual Summary File. Prevalence for 2027 was forecasted with US Census population projections. Regional projections were based on applying national OAB rates by age, sex, and race/ethnicity to zip code tabulation area beneficiary populations. Results: In the 2013 dataset, the prevalence of OAB was 7.2% (male: 7.7%; female: 6.7%). Across demographic categories, prevalence was the highest among those aged more than 74 years (9.3%), identifying as White (7.4%), and residing in urban areas (7.5%). By 2027, OAB is projected to increase by 48.1%. Discussion: OAB affects a substantial proportion of the US fee-for-service beneficiary population, with the prevalent population projected to rise substantially by 2027.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在医保人群中膀胱过动症的患病率和预测患病率
目的:确定目前和未来膀胱过动症(OAB)在美国医疗保险服务收费受益人中的患病率。方法:使用2013年医疗保险受益人B部分携带者索赔文件、D部分药物事件文件和医疗保险受益人年度摘要文件确定美国成年人小于65岁的OAB患病率。2027年的患病率是根据美国人口普查预测预测的。区域预测是基于按年龄、性别和种族/民族将国家OAB率应用于邮政编码制表地区的受益人口。结果:在2013年的数据集中,OAB的患病率为7.2%(男性:7.7%;女:6.7%)。在人口统计类别中,74岁以上人群(9.3%)、白人(7.4%)和居住在城市地区(7.5%)的患病率最高。到2027年,OAB预计将增长48.1%。讨论:OAB影响了相当大比例的美国按服务收费的受益人口,预计到2027年,流行人口将大幅增加。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The Prevalence and Forecast Prevalence of Overactive Bladder in the Medicare Population Clinical Outcomes of Retrograde Intrarenal Surgery as a Primary Treatment for Staghorn Calculi: A Single-Center Experience Urinary pH as a Target in the Management of Lithiasic Patients in Real-World Practice: Monitoring and Nutraceutical Intervention for a Nonlithogenic pH Range Role of Serum and Urinary Biomarkers in Evaluation and Management of Patients With Overactive Bladder Treatment of Metastatic Renal Cell Carcinoma: Latest Evidence and Ongoing Challenges
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1